정지영 (University of California, Irvine)

한빛사논문

조회1,072

University of California, Irvine

CV File 154 kb

Adv. Drug Deliv. Rev., Available online 24 December 2020 | https://doi.org/10.1016/j.addr.2020.12.011 COVID-19 vaccines: The status and perspectives in delivery points of view

Jee Young Chung^a, Melissa N. Thone^a, Young Jik Kwon^a,b,c,d,*

^aDepartment of Pharmaceutical Sciences, University of California, Irvine, CA 92697, United States of America
^bDepartment of Chemical and Biomolecular Engineering, University of California, Irvine, CA 92697, United States of America
^cDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, United States of America
^dDepartment of Biomedical Engineering, University of California, Irvine, CA 92697, United States of America

^*Corresponding author

Abstract

Due to the high prevalence and long incubation periods often without symptoms, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals globally, causing the coronavirus disease 2019 (COVID-19) pandemic. Even with the recent approval of the anti-viral drug, remdesivir, and Emergency Use Authorization of monoclonal antibodies against S protein, bamlanivimab and casirimab/imdevimab, efficient and safe COVID-19 vaccines are still desperately demanded not only to prevent its spread but also to restore social and economic activities via generating mass immunization. Recent Emergency Use Authorization of Pfizer and BioNTech’s mRNA vaccine may provide a pathway forward, but monitoring of long-term immunity is still required, and diverse candidates are still under development. As the knowledge of SARS-CoV-2 pathogenesis and interactions with the immune system continues to evolve, a variety of drug candidates are under investigation and in clinical trials. Potential vaccines and therapeutics against COVID-19 include repurposed drugs, monoclonal antibodies, antiviral and antigenic proteins, peptides, and genetically engineered viruses. This paper reviews virology and immunology of SARS-CoV-2, alternative therapies for COVID-19 to vaccination, principles and design considerations in COVID-19 vaccine development, and the promises and roles of vaccine carriers in addressing the unique immunopathological challenges presented by the disease.

Keywords : Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immune response, Neutralizing antibodies, Vaccine delivery

논문정보

형식Review Paper
게재일2020년 12월 (BRIC 등록일 2020-12-31)
연구진국외 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기